Skip to main content

Advertisement

SpringerLink
Log in

Effect of High-Dose Aspirin on Helicobacter pylori Eradication

  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

We conducted a pilot study aimed at comparing the efficacy of the standard OAC (omeprazole–amoxicillin–clarithromycin) regimen with a combination of the OAC regimen and aspirin (OACA). Follow-up endoscopic findings showed that the previous ulcers were completely healed in all subjects. The eradication rates (per protocol) were 80.3% (49/61) in the OAC group and 86.7% (52/60) in the OACA group. The eradication rate was not significantly different between the two groups. The most common adverse event was a bad taste, and the overall adverse events were similar in the two groups. The combination of the OAC regimen and aspirin was not significantly superior to the standard OAC regimen, but it was well tolerated in a group of patients with peptic ulcer disease. Its potential for clinical use to augment the efficacy of H. pylori eradication may warrant further investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Hunt RH: Eradication of Helicobacter pylori infection. Am J Med 100(5A):S42–S50, 1996

    Google Scholar 

  2. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. J Am Med Assoc 272:65–69, 1994

    Google Scholar 

  3. Ulmer HJ, Beckerling A, Gatz G: Recent use of proton pump inhibitor-based triple therapies for the eradication of H pylori: a broad data review. Helicobacter 8:95–104, 2003

    PubMed  CAS  Google Scholar 

  4. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY: Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 161:1217–1220, 2001

    PubMed  CAS  Google Scholar 

  5. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D, Zhang J, Bhattacharyya H, King EC, Hopkins RJ: Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993–1999. Ann Intern Med 136:13–24, 2002

    PubMed  Google Scholar 

  6. Caselli M, Pazzi P, LaCorte R, Aleotti A, Trevisani L, Stabellini G: Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. Digestion 44:101–104, 1989

    Article  PubMed  CAS  Google Scholar 

  7. Wang WH, Wong WM, Dailidiene D, Berg DE, Gu Q, Lai KC, Lam SK, Wong BC: Aspirin inhibits the growth of Helicobacter pylori and enhances its susceptibility to antimicrobial agents. Gut 52:490–495, 2003

    PubMed  CAS  Google Scholar 

  8. Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 20:1161–1181, 1996

    Article  CAS  PubMed  Google Scholar 

  9. Laine L, Cominelli F, Sloane R, Casini-Raggi V, Marin-Sorensen M, Weinstein WM: Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial. Aliment Pharmacol Ther 9:127–135, 1995

    Article  PubMed  CAS  Google Scholar 

  10. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W: Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 114:245–255, 1998

    PubMed  CAS  Google Scholar 

  11. Cryer B, Feldman M: Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117:17–25, 1999

    PubMed  CAS  Google Scholar 

  12. Hudson N, Balsitis M, Filipowicz F, Hawkey CJ: Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34:748–751, 1993

    PubMed  CAS  Google Scholar 

  13. Konturek SJ, Bielanski W, Plonka M, Pawlik T, Pepera J, Konturek PC, Czarnecki J, Penar A, Jedrychowski W: Helicobacter pylori, non-steroidal anti-inflammatory drugs and smoking in risk pattern of gastroduodenal ulcers. Scand J Gastroenterol 38:923–930, 2003

    PubMed  CAS  Google Scholar 

  14. Louw JA, van Rensburg CJ, Hanslo D, Grundlings HD, Girdwood AH, Marks IN: Two week course of pantoprazole combined with 1 week of amoxycillin and clarithromycin is effective in Helicobacter pylori eradication and duodenal ulcer healing. Aliment Pharmacol Ther 12:545–550, 1998

    PubMed  CAS  Google Scholar 

  15. Maconi G, Parente F, Russo A, Vago L, Imbesi V, Porro GB: Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy? Am J Gastroenterol 96:359–366, 2001

    PubMed  CAS  Google Scholar 

  16. Megraud F, Lehn N, Lind T, Bayerdorffer E, O’Morain C, Spiller R, Unge P, van Zanten SV, Wrangstadh M, Burman CF: Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 43:2747–2752, 1999

    PubMed  CAS  Google Scholar 

  17. Hoshiya S, Watanabe K, Tokunaga K, Tanaka A, Ninomiya H, Shingaki M, Itoh T, Saito S, Ishida H, Takahashi S: Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan. J Gastroenterol 35:10–14, 2000

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

    Seung Ha Park MD, Dong Il Park MD, Sang Hoon Kim MD, Hong Joo Kim MD, Yong Kyun Cho MD, In Kyung Sung MD, Chong Il Sohn MD, Woo Kyu Jeon MD & Byung Ik Kim MD

  2. Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

    Dong Keuk Keum MD

  3. 108 Pyung-Dong, Jongro-Ku, Seoul, Korea, 110-746

    Dong Il Park MD

Authors
  1. Seung Ha Park MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dong Il Park MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sang Hoon Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Joo Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Kyun Cho MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. In Kyung Sung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chong Il Sohn MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Woo Kyu Jeon MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Byung Ik Kim MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Dong Keuk Keum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Il Park MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Park, S.H., Park, D., Kim, S.H. et al. Effect of High-Dose Aspirin on Helicobacter pylori Eradication. Dig Dis Sci 50, 626–629 (2005). https://doi.org/10.1007/s10620-005-2547-3

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-005-2547-3

Keywords

Search

Navigation